Trice Medical CEO and leadership

Jeffrey O’Donnell, Sr. brings more than 25 years of Board and Chief Executive experience running emerging medical device firms. Businesses under his direct leadership have achieved over $1.5 Billion in value creation from initial public offering of stock or mergers and acquisitions. Currently, Jeff is currently a managing director at O’Donnell Partners, a healthcare consulting firm. Jeff is also currently a Venture Partner at Laidlaw Venture Partners and The Managing Director of Runway Healthcare a MedTec Accelerator. O’Donnell retired as CEO and founder of Trice Medical an emerging growth medical device company developing in office arthroscopy tools. In 2008, Jeff founded and ran Embrella Cardiovascular, a medical device startup company, which was sold in 2011 to Edwards Lifesciences (NYSE: EW). Prior to Embrella Cardiovascular, Jeff served as President and CEO of PhotoMedex (NASDAQ: PHMD) from 1999 to 2009. Prior to PhotoMedex, Jeff was the President and CEO of Cardiovascular Dynamics. His team took CCVD public on NASDAQ in June of 1996 and purchased Radiance Medical Systems and Endologix (NASDAQ: ELGX). From 1994 to 1995 Jeff held the position of President and CEO of Kensey Nash Corporation (NASDAQ: KNSY). Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and with Johnson & Johnson’s Orthopedic Division. In 2005, Jeff was named LifeSciences CEO of the Year by Price Waterhouse Coopers. In 2011, Jeff was named the Greater Philadelphia Emerging Entrepreneur of The Year by Ernst & Young. In 2017, Jeff assumed the role of Chairman of the Board of Directors for SpectraWave, a cardiology device company. He is also currently the lead Director for BioSig Technologies and a member of the Board of Directors for Trice Medical. He joined the AdvaMed Accel Board of Directors in 2016 and serves as an observer on the Membership, Ethics and Technology and Regulatory committees of the AdvaMed Board. Previously, Jeff served as Chairman of the Board for Strata Skin Sciences (NASDAQ: SSKN) (2 years), as well as a Director on the Board at Cardiac Science (7 yrs.) and Endologix (12 yrs.). Jeff is a graduate of LaSalle University and recently inducted into the Beta Gamma Sigma, an international honors society.

Executive leader with a strong, diverse background in finance, operations, and business development. 20 years of experience with both private and public emerging growth, life science companies, including 8+ years serving as CFO. Demonstrated success and significant business performance improvements across multiple corporate functions to drive financial performance through organic revenue growth, acquisitions, and operational efficiencies. Significant experience in raising capital, having secured in excess of $60mm in equity and debt financing to support corporate growth initiatives.

Cynthia Davis is a CFO at Trice Medical.

Medical Device executive with a proven record of developing and commercializing clinically valuable technologies. Skilled at leading the transformation of concepts through development, manufacturing and market release. Combines strong product development and relationship building skill sets with an insightful understanding of physician, patient and payor needs. Diverse range of experience in market development, sales training and operations, product and strategic marketing, surgeon relations, IP portfolio management, project management of regulated devices, fundraising and investor relations. Passionate about creating innovative solutions, teamwork and successfully delivering company revenue and growth.

Ryan Hartman is a Chief Commercial Officer (CCO) at Trice Medical and is based in Malvern, Pennsylvania. He has worked as Vice President of Marketing, Single Use Scopes & Global Markets at Boston Scientific and Territory Manager(Field Development Manager) at Boston Scientific. Ryan attended SUNY New Paltz between 1995 and 1997 and New School/The between 1997 and 2000.

Jeffrey O’Donnell, Sr. brings more than 25 years of Board and Chief Executive experience running emerging medical device firms. Businesses under his direct leadership have achieved over $1.5 Billion in value creation from initial public offering of stock or mergers and acquisitions. Currently, Jeff is currently a managing director at O’Donnell Partners, a healthcare consulting firm. Jeff is also currently a Venture Partner at Laidlaw Venture Partners and The Managing Director of Runway Healthcare a MedTec Accelerator. O’Donnell retired as CEO and founder of Trice Medical an emerging growth medical device company developing in office arthroscopy tools. In 2008, Jeff founded and ran Embrella Cardiovascular, a medical device startup company, which was sold in 2011 to Edwards Lifesciences (NYSE: EW). Prior to Embrella Cardiovascular, Jeff served as President and CEO of PhotoMedex (NASDAQ: PHMD) from 1999 to 2009. Prior to PhotoMedex, Jeff was the President and CEO of Cardiovascular Dynamics. His team took CCVD public on NASDAQ in June of 1996 and purchased Radiance Medical Systems and Endologix (NASDAQ: ELGX). From 1994 to 1995 Jeff held the position of President and CEO of Kensey Nash Corporation (NASDAQ: KNSY). Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and with Johnson & Johnson’s Orthopedic Division. In 2005, Jeff was named LifeSciences CEO of the Year by Price Waterhouse Coopers. In 2011, Jeff was named the Greater Philadelphia Emerging Entrepreneur of The Year by Ernst & Young. In 2017, Jeff assumed the role of Chairman of the Board of Directors for SpectraWave, a cardiology device company. He is also currently the lead Director for BioSig Technologies and a member of the Board of Directors for Trice Medical. He joined the AdvaMed Accel Board of Directors in 2016 and serves as an observer on the Membership, Ethics and Technology and Regulatory committees of the AdvaMed Board. Previously, Jeff served as Chairman of the Board for Strata Skin Sciences (NASDAQ: SSKN) (2 years), as well as a Director on the Board at Cardiac Science (7 yrs.) and Endologix (12 yrs.). Jeff is a graduate of LaSalle University and recently inducted into the Beta Gamma Sigma, an international honors society.

Jeffrey O’Donnell, Sr. brings more than 25 years of Board and Chief Executive experience running emerging medical device firms. Businesses under his direct leadership have achieved over $1.5 Billion in value creation from initial public offering of stock or mergers and acquisitions. Currently, Jeff is currently a managing director at O’Donnell Partners, a healthcare consulting firm. Jeff is also currently a Venture Partner at Laidlaw Venture Partners and The Managing Director of Runway Healthcare a MedTec Accelerator. O’Donnell retired as CEO and founder of Trice Medical an emerging growth medical device company developing in office arthroscopy tools. In 2008, Jeff founded and ran Embrella Cardiovascular, a medical device startup company, which was sold in 2011 to Edwards Lifesciences (NYSE: EW). Prior to Embrella Cardiovascular, Jeff served as President and CEO of PhotoMedex (NASDAQ: PHMD) from 1999 to 2009. Prior to PhotoMedex, Jeff was the President and CEO of Cardiovascular Dynamics. His team took CCVD public on NASDAQ in June of 1996 and purchased Radiance Medical Systems and Endologix (NASDAQ: ELGX). From 1994 to 1995 Jeff held the position of President and CEO of Kensey Nash Corporation (NASDAQ: KNSY). Additionally, he has held several senior sales and marketing management positions at Boston Scientific Corporation, Guidant Corporation and with Johnson & Johnson’s Orthopedic Division. In 2005, Jeff was named LifeSciences CEO of the Year by Price Waterhouse Coopers. In 2011, Jeff was named the Greater Philadelphia Emerging Entrepreneur of The Year by Ernst & Young. In 2017, Jeff assumed the role of Chairman of the Board of Directors for SpectraWave, a cardiology device company. He is also currently the lead Director for BioSig Technologies and a member of the Board of Directors for Trice Medical. He joined the AdvaMed Accel Board of Directors in 2016 and serves as an observer on the Membership, Ethics and Technology and Regulatory committees of the AdvaMed Board. Previously, Jeff served as Chairman of the Board for Strata Skin Sciences (NASDAQ: SSKN) (2 years), as well as a Director on the Board at Cardiac Science (7 yrs.) and Endologix (12 yrs.). Jeff is a graduate of LaSalle University and recently inducted into the Beta Gamma Sigma, an international honors society.